The t(14;18) (q32;ql) chromosomal translocation is a consistent feature of follicular lymphoma (FL) . Approximately 85% of FL patients and one-third of patients with diffuse large-cell lymphoma (DLCL) carry the t(14;18) (q32;q21) translocation in tissue specimens, as judged by cytogenic and molecular studies (Yunis et al., 1982; Lee et al., 1987a; Weiss et al., 1987; Ngan et al., 1988; Aisenberg et al., 1988) . This translocation results in the juxtaposition of the bcl-2 protooncogene located on chromosome 18 with the immunoglobulin heavy chain gene (JH) on chromosome 14 (Tsujimoto et al., 1984; Bakhshi et al., 1985; Cleary et al., 1986a ). The breakpoints occur at two sites on chromosome 18: the 'major breakpoint region' (MBR) and a 'minor cluster region' (mcr) (Tsujimoto et al., 1985; Cleary & Sklar, 1985; Cleary et al., 1986b; Ngan et al., 1989) . New evidence suggests that the bcl-2 gene may play a role in suppressing programmed cell death within lymphoid cells (McDonnell et al., 1989; Hockenbery et al., 1991) . The fact that most translocations cluster in an extremely small area has encouraged investigators to analyse the t(14;18) breakpoint by the polymerase chain reaction (PCR) (Lee et al., 1987b; Crescenzi et al., 1988; Stetler-Stevenson et al., 1988; Ngan et al., 1989; Cotter et al., 1990 ). The tumour marker can be detected with high sensitivity by using primers specific to the bcl-2/JH translocated gene sequences, and one tumour cell can be detected among 105-106 normal cells (Crescenzi et al., 1988; Stetler-Stevenson et al., 1988) .
Bone marrow involvement in NHL is common in certain subtypes at onset or during the course of the disease, and patients with bone marrow involvement run a substantial risk of tumour recurrence (Dick et al., 1974; Rosenberg, 1975; Stein et al., 1976; Simon et al., 1988 (Higuchi, 1989) . The pellet containing mononuclear cells was resuspended (5 x 106 cells per I ml) in 100mM NaCl, 25mM EDTA, 0.5% SDS and 200 sgml-' proteinase K (Sigma, St Louis, MO) and incubated overnight at 37°C. DNA was extracted by phenol-chloroform and precipitated with ethanol. Eight samples with small numbers of cells were prepared by resuspension in digestion mixture (1 x PcR buffer, 0.25% Tween 20, 0.6 yl of 10 mg ml-' proteinase K per 100 ;LI) at a concentration of 5 x I05 cell ml-' and incubated at 56°C for 2'h followed by a 95°C 20 min inactivation step to inhibit proteinase K (Kawasaki, 1990 (Table III) . peripheral blood and bone marrow findings are closely correlated this may no longer be true after treatment. We observed three patients with FL in whom peripheral blood became t(14;18)-negative following chemotherapy (single agent chlorambucil) while the bone marrow remained clearly positive. These data are very preliminary and a large number of patients will be followed prospectively.
Discussion
The utility of molecular monitoring in the assessment of lymphoma patients is still controversial: conflicting results have been published on the prognostic significance of bcl-2 protein expression and/or bcl-2 gene rearrangements (Yunis et al., 1989; Price et al., 1991; Pezzella et al., 1992) . In this study we assessed the usefulness of bcl-2/JH PCR as a means for improving the detection of lymphoma cells in the bone marrow of follicular lymphoma and intermediategrade NHL patients. Half of the early-stage FL patients with morphologically normal marrow had amplifiable breakpoints, and we found that the marrow compartments, even in stage I and II patients, frequently contained lymphoma cells when tested by PCR. Thus bcl-2/JH PCR assessment in early-stage FL can result in upstaging many patients and may be of considerable interest to the clinician.
The possibility of an easy detection of bcl-2/JH rearrangement may also be useful in diffuse large-cell or mixed-cell lymphomas where it may be associated with a relatively poor prognosis (Yunis et al., 1989) and may indicate a morphological transformation from a FL to a more aggressive histologic subtype (Lee et al., 1987a) . In the intermediategrade patients we found bcl-2/JH rearrangements in approximately 34% of bone marrow and peripheral blood samples. This finding is consistent with other studies reporting an overall frequency of approximately 20%-40% of the t(14;18) in this group of patients (Yunis et al., 1982; Lee et al., 1987a; Aisenberg et al., 1988; Yunis et al., 1989; Lambrechts et al., 1992) .
The most interesting finding in our study was the striking correlation between bcl-2/JH positivity in the peripheral blood and the corresponding bone marrow sample. Paired samples showed concordance in virtually all cases. We believe that our data accurately reflect the status of the tissue samples and are not a consequence of cross-contamination or false positive results, because in all cases where bone marrow DNA was negative, the corresponding peripheral blood sample contained no detectable specific PCR product. In addition, the migration patterns on agarose gel suggested that the results were not due to contamination because the size of the PCR products varied from patient to patient. This observation suggests that the peripheral blood-a readily accessible tissue-provides considerable ancillary information in earlystage follicular lymphoma patients. Peripheral blood may in fact provide nearly the same information as the bone marrow aspirate. Therefore, it may reduce the need for more invasive examinations. Similar results, with a lesser degree of concordance between bone marrow and peripheral blood analysis, have recently been published (Hickish et al., 1991) indicating the PCR can be an effective means for clinical monitoring of low-grade lymphomas. However, the clinical significance of detecting minimal disease in bone marrow by PCR has still to be established and will require prolonged follow-up because of the natural history of FL with a median survival than can exceed 8 years in advanced stages. Serial samples from patients undergoing chemotherapy suggest that after treatment the peripheral blood and bone marrow may show divergent results and a larger number of patients will be followed prospectively to confirm this very preliminary finding whose biological significance is yet unclear. One possibility is that circulating cells with the t(14;18) have altered properties (e.g. loss of adhesion) modifying their clinical behaviour. The clinical relevance of the persistence of PCRdetectable neoplastic cells in the blood and in the bone marrow may also be different for the different types of lymphomas. Further studies on serial samples from patients are needed to determine the usefulness of bcl-2/JH PCR detection post-therapy. In fact, it has recently been shown that aggressive chemotherapy often fails to eradicate bcl-2/ JH-positive cells from the marrow even when this becomes morphologically negative (Gribben et al., 1991) and that circulating cells carrying t(14;18) may be found in some long remissions of advanced FL (Price et al., 1991; Lambrechts et al., 1992) but not in patients initially with truly localised disease (Price et al., 1991 ). An accurate quantification of the PCR analysis would be very helpful for clarifying many issues, development of reliable procedures is ongoing.
